Rxsight Net Worth

Rxsight Net Worth Breakdown

  RXST
The net worth of Rxsight is the difference between its total assets and liabilities. Rxsight's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Rxsight's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Rxsight's net worth can be used as a measure of its financial health and stability which can help investors to decide if Rxsight is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Rxsight stock.

Rxsight Net Worth Analysis

Rxsight's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rxsight's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rxsight's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rxsight's net worth analysis. One common approach is to calculate Rxsight's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rxsight's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rxsight's net worth. This approach calculates the present value of Rxsight's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rxsight's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rxsight's net worth. This involves comparing Rxsight's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rxsight's net worth relative to its peers.

Enterprise Value

685.3 Million

To determine if Rxsight is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rxsight's net worth research are outlined below:
Rxsight generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 139.93 M. Net Loss for the year was (27.45 M) with profit before overhead, payroll, taxes, and interest of 98.94 M.
Rxsight currently holds about 128.62 M in cash with (16.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.65.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 7000 shares by Fountain Tamara of Rxsight at 25.7145 subject to Rule 16b-3
Rxsight uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rxsight. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rxsight's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Rxsight Target Price Consensus

Rxsight target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Rxsight's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   10  Strong Buy
Most Rxsight analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Rxsight stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Rxsight, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Rxsight Target Price Projection

Rxsight's current and average target prices are 25.84 and 58.00, respectively. The current price of Rxsight is the price at which Rxsight is currently trading. On the other hand, Rxsight's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Rxsight Market Quote on 16th of March 2025

Low Price25.11Odds
High Price25.96Odds

25.84

Target Price

Analyst Consensus On Rxsight Target Price

Low Estimate52.78Odds
High Estimate64.38Odds

58.0

Historical Lowest Forecast  52.78 Target Price  58.0 Highest Forecast  64.38
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Rxsight and the information provided on this page.

Know Rxsight's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Rxsight is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rxsight backward and forwards among themselves. Rxsight's institutional investor refers to the entity that pools money to purchase Rxsight's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Divisadero Street Capital Management, Lp2024-12-31
812.5 K
Deutsche Bank Ag2024-12-31
657.2 K
Crédit Agricole S.a.2024-12-31
592 K
Royal Bank Of Canada2024-12-31
508.5 K
No Street Gp Lp2024-12-31
500 K
Gilder Gagnon Howe & Co Llc2024-12-31
425.3 K
Df Dent & Co Inc2024-12-31
422.4 K
Atika Capital Management Llc2024-12-31
408.6 K
Northern Trust Corp2024-12-31
403.4 K
Ra Capital Management, Llc2024-12-31
3.7 M
Blackrock Inc2024-12-31
M
Note, although Rxsight's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Rxsight's market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.05 B.

Market Cap

676.77 Million

Project Rxsight's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.08)
Return On Capital Employed(0.13)(0.13)
Return On Assets(0.09)(0.08)
Return On Equity(0.10)(0.10)
The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.21.
When accessing Rxsight's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rxsight's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rxsight's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Rxsight's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rxsight. Check Rxsight's Beneish M Score to see the likelihood of Rxsight's management manipulating its earnings.

Evaluate Rxsight's management efficiency

Rxsight has return on total asset (ROA) of (0.0919) % which means that it has lost $0.0919 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1243) %, meaning that it created substantial loss on money invested by shareholders. Rxsight's management efficiency ratios could be used to measure how well Rxsight manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.08 in 2025. Return On Capital Employed is likely to drop to -0.13 in 2025. Change To Liabilities is likely to gain to about 6.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 17.4 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 7.24  7.60 
Tangible Book Value Per Share 7.24  7.60 
Enterprise Value Over EBITDA(56.05)(53.25)
Price Book Value Ratio 4.75  4.99 
Enterprise Value Multiple(56.05)(53.25)
Price Fair Value 4.75  4.99 
Enterprise Value1.3 B685.3 M
Leadership at Rxsight emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue
5.8655
Revenue
139.9 M
Quarterly Revenue Growth
0.407
Revenue Per Share
3.6
Return On Equity
(0.12)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rxsight insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rxsight's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rxsight insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Fountain Tamara few days ago
Disposition of 7000 shares by Fountain Tamara of Rxsight at 25.7145 subject to Rule 16b-3
 
Maniar Shweta over a month ago
Disposition of 3519 shares by Maniar Shweta of Rxsight at 30.8662 subject to Rule 16b-3
 
Corley Jesse Anderson over a month ago
Acquisition by Corley Jesse Anderson of 1767 shares of Rxsight at 31.1286 subject to Rule 16b-3
 
Corley Jesse Anderson over a month ago
Acquisition by Corley Jesse Anderson of 1443 shares of Rxsight at 31.185 subject to Rule 16b-3
 
Ilya Goldshleger over two months ago
Disposition of 1173 shares by Ilya Goldshleger of Rxsight at .7293 subject to Rule 16b-3
 
Ilya Goldshleger over two months ago
Disposition of 2900 shares by Ilya Goldshleger of Rxsight at 54.9616 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 45.88 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of tradable shares by Ilya Goldshleger of Rxsight at 45.07 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of 260 shares by Ilya Goldshleger of Rxsight at 51.7372 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.643 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.6778 subject to Rule 16b-3
 
Ilya Goldshleger over three months ago
Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.7799 subject to Rule 16b-3

Rxsight Corporate Filings

F4
13th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
25th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
13th of February 2025
Other Reports
ViewVerify
Rxsight time-series forecasting models is one of many Rxsight's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rxsight's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Rxsight Earnings Estimation Breakdown

The calculation of Rxsight's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Rxsight is estimated to be -0.27 with the future projection ranging from a low of -0.1617 to a high of 0.02. Please be aware that this consensus of annual earnings estimates for Rxsight is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.03
-0.16
Lowest
Expected EPS
-0.27
0.02
Highest

Rxsight Earnings Projection Consensus

Suppose the current estimates of Rxsight's value are higher than the current market price of the Rxsight stock. In this case, investors may conclude that Rxsight is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Rxsight's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
1062.14%
0.03
-0.27
-0.71

Rxsight Earnings per Share Projection vs Actual

Actual Earning per Share of Rxsight refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Rxsight predict the company's earnings will be in the future. The higher the earnings per share of Rxsight, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Rxsight Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Rxsight, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Rxsight should always be considered in relation to other companies to make a more educated investment decision.

Rxsight Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Rxsight's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-26
2024-12-31-0.00860.030.0386448 
2024-11-08
2024-09-30-0.072-0.16-0.088122 
2024-08-05
2024-06-30-0.22-0.160.0627 
2024-05-06
2024-03-31-0.27-0.250.02
2024-02-28
2023-12-31-0.36-0.260.127 
2023-11-09
2023-09-30-0.43-0.310.1227 
2023-08-07
2023-06-30-0.47-0.390.0817 
2023-05-09
2023-03-31-0.53-0.420.1120 
2023-03-06
2022-12-31-0.75-0.560.1925 
2022-11-07
2022-09-30-0.71-0.610.114 
2022-08-08
2022-06-30-0.69-0.610.0811 
2022-05-05
2022-03-31-0.65-0.640.01
2022-03-08
2021-12-31-0.68-0.580.114 
2021-11-10
2021-09-30-0.62-0.68-0.06
2021-09-09
2021-06-30-0.7-0.510.1927 
2021-06-02
2021-03-310-0.36-0.36
2021-03-31
2020-12-310-1.7028-1.7028

Rxsight Corporate Management

Matt HallerChief OfficerProfile
Alex HuangInvestor RelationsProfile
Oliver MoravcevicVice RelationsProfile
Patrick CullenExecutive OperationsProfile
Scott GainesExecutive OperationsProfile

Additional Tools for Rxsight Stock Analysis

When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.